YooYoung Pharmaceutical

What YooYoung Pharmaceutical does

YooYoung Pharmaceutical (유영제약, founded 1981) is a privately held Korean specialty pharmaceutical and medical device manufacturer headquartered in Seoul with primary manufacturing operations in Jincheon, Chungcheongbuk-do. The company develops, manufactures, and commercializes finished pharmaceutical products — oral solid dosages, prefilled syringes, ampoule injections — and hyaluronic acid-based medical devices, with portfolio focus on osteoarthritis treatments (Resyno-one, Atri, Atriplus), aesthetic medicine (DivaViva dermal filler series), chronic disease (Lucalo for constipation, Pravafenix for hyperlipidemia), and cell therapy (NeuroNata-R, the world's first approved stem cell treatment for ALS, co-developed with Corestem). Manufacturing is anchored by an EU-GMP compliant Jincheon facility with annual capacity of 800 million tablets, 25 million ampoules, and 15 million prefilled syringes, and the company holds a dense stack of regulatory certifications including KGMP, Japan PMDA GMP, CE Mark, ISO 13485, PIC/S GMP, BGMP, Kenya PPB GMP, and Taiwan TFDA QSD.

The company operates a hybrid revenue model combining direct domestic sales to Korean healthcare providers (hospitals, clinics, pharmacies), multi-jurisdiction exports (USD 10M+ annually across Japan, Asia, Europe, South America, and more recently China and Spain), exclusive distribution partnerships (notably Atriplus in the EU), licensing-in and licensing-out royalty arrangements (Pravafenix, BEMFOLA, SIMDAX, NS-126), and contract manufacturing (CMO) services for solid formulations and prefilled syringes to third-party pharmaceutical companies. Customer base is structurally diversified across domestic healthcare, international distributors, CMO clients, and end patients. Growth has been supported by progressive export expansion (USD 1M in 2009 → USD 10M in 2021 Export Tower awards), facility expansion (2007 EU-GMP 2nd factory, 2022 PFS line, 2023 storage facility), and a five-asset R&D pipeline targeting hyperlipidemia, anti-diabetic, skin booster, and osteoarthritis cell therapy indications. The company is family-controlled, with the second-generation CEO Jupyong Yoo assuming leadership in 2023, and remains privately held with no disclosed institutional investor or funding round activity.

Name

YooYoung Pharmaceutical

Legal name

(주)유영제약

Website

https://yypharm.co.kr

Company type

Private

Founded year

1981

Operating status

Operating

Headcount range

51–100 employees

Short description

YooYoung Pharmaceutical is a Korean specialty pharmaceutical and medical device manufacturer (founded 1981) producing osteoarthritis injections, hyaluronic acid dermal fillers, and a world-first ALS stem cell therapy for domestic healthcare providers, international distributors, and CMO clients.

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), Surgical and Medical Instrument Manufacturing (339112)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Oral Solid Dose (OSD) Generics (HLAIABAD)

Keywords

• Pharmaceutical manufacturing
• Injectable drug production
• Hyaluronic acid formulations
• Prefilled syringe manufacturing
• Contract pharmaceutical services

Headquarters

HQ city

Seoul

HQ country

South Korea

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Product Sales: Manufacturing and selling of finished drug products including oral solid dosage (OSD) tablets, prefilled syringes, ampoules for injections, and specialty generic medications. Revenue is generated through domestic sales to healthcare providers and international exports to Japan, Asia, Europe, and South America.
2. Licensing and Technology Transfer: Revenue from licensing agreements for proprietary technologies and products, including license-out agreements for products like Pravafenix, BEMFOLA, and SIMDAX, as well as license-in arrangements for new drug development.
3. Medical Device Sales: Sales of hyaluronic acid-based medical devices including dermal fillers (DivaViva series) and injectable treatments for osteoarthritis.
4. Contract Manufacturing (CMO): Contract manufacturing services offered to other pharmaceutical companies for solid formulations (uncoated tablets, coated tablets, hard capsules) and prefilled syringe formulations (1, 3, 5 mL).

Go-to-market motion2 records

Distribution channels4 records

Marketing channels5 records

Core offering

YooYoung Pharmaceutical manufactures and sells finished pharmaceutical products including oral solid dosage (OSD) tablets, prefilled syringes, and ampoule injections at its EU-GMP compliant Jincheon facility. The company also produces hyaluronic acid-based medical devices such as dermal fillers (DivaViva series) and arthritis injection treatments (Atri/Atriplus), and offers contract manufacturing (CMO) services for solid formulations and prefilled syringes to other pharmaceutical companies.

Product overview

YooYoung Pharmaceutical is a Korean pharmaceutical company offering a diversified portfolio of prescription drugs and medical devices. The company manufactures finished drug products including oral solid dosages, prefilled syringes, and ampoule injections at its KGMP-certified Jincheon factory. Key products include innovative new drugs (Resyno-one for osteoarthritis, NeuroNata-R for ALS as world's first stem cell treatment), hyaluronic acid-based medical devices (DivaViva filler series, Atri/Atri Plus for arthritis), and specialty generic medications. The R&D pipeline focuses on hyperlipidemia, anti-diabetic treatments, skin boosters, and cell therapies for osteoarthritis.

Differentiator

Problem solved

Functional benefit

Brands

• DivaViva: Dermal HA Filler series - independently developed and clinically completed dermal hyaluronic acid filler for wrinkle improvement
• NeuroNata-R
• Resyno-one (레시노원주)
• Atri (아트리)

Products and services

• Resyno-one Injection (레시노원주) Novel single-use injection for the treatment of hip osteoarthritis, developed as an innovative new drug by YooYoung Pharmaceutical.
• NeuroNata-R (뉴로나타-알주) World's first stem cell treatment for Amyotrophic Lateral Sclerosis (Lou Gehrig's disease), co-developed with Corestem and marketed as a treatment for rare neurodegenerative disease.
• DivaViva Series (디바비바 시리즈) Independently developed dermal hyaluronic acid filler series for wrinkle improvement and aesthetic/cosmetic medical applications, part of the Health & Beauty product line.
• Atri / Atriplus Injection (아트리/아트리플러스주) Hyaluronic acid-based arthritis treatment injection with CE Mark certification for the European market and exclusive EU sales partnership.
• Lucalo Tablets (루칼로정) Oral chronic constipation treatment medication launched for the domestic Korean market.
• Pravafenix Capsule (프라바페닉스캡슐) Hyperlipidemia combination product licensed from SMB (Laboratorios SMB) for distribution in the Korean market.
• Yooridion Injection (유리디온주) Injectable pharmaceutical product launched as part of the company's injectables portfolio.
• Pioda Tablets (피오다정) Oral solid dosage pharmaceutical product launched in 2024 as part of the company's OSD portfolio.
• Contract Manufacturing (CMO) Services Contract manufacturing services for pharmaceutical companies covering solid formulations (uncoated tablets, coated tablets, hard capsules) and prefilled syringe formulations (1, 3, 5 mL) at the EU-GMP certified Jincheon facility.

Quantifiable outcome

• Revenue surpassed KRW 100 billion in 2019
• +2 more outcomes

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Seven partnerships are on record, tiered strategic, core and minor.

• NovozymestrategicTechnology or Integration · 26 February 2013Technology license-in contract for development of YY1201 enzyme-based pharmaceutical product.
• National Onco VenturecoreStrategic or Co-development Partner · 8 February 2013Technology transfer contract for YYB-101 antibody novelty medication for cancer treatment development.
• European Distributor (EU)strategicChannel Partner/ Reseller/ Distributor · 5 October 2012Exclusive sales contract for Atriplus injection in European (EU) regions, marking Yooyoung's expansion into European pharmaceutical markets.
• CorestemcoreStrategic or Co-development Partner · 22 March 2011Partnership for co-research and licensure of stem cell treatment for Lou Gehrig's disease (ALS), resulting in the world's first stem cell therapy NeuroNata-R launched in 2015. This partnership positioned Yooyoung as a pioneer in cell therapy for rare diseases.
• SMB (Laboratorios SMB)strategicStrategic or Co-development Partner · 10 November 2009License agreement for Pravafenix (hyperlipidemia combination product) enabling international distribution of specialty generic product.
• Nippon Shinyaku (Japan)strategicStrategic or Co-development Partner · 5 June 2008License contract for allergic rhinitis treatment medication NS-126 with Japanese pharmaceutical company Nippon Shinyaku.
• Markit (주)마크잇minorImplementation/ SI/ Consulting PartnerWebsite development and operations (maintenance/repair) partner. Website development and management services commissioned to external professional company.

Scale indicators8 records

Recent moves12 records

Expansion highlights6 records

Broad incumbents

• Dong-A Pharmaceutical: Established Korean pharma with a broad finished-drug product portfolio (OSD, injectables, biologics) and growing overseas operations — comparable category breadth but larger and more diversified.
• AbbVie (Allergan Aesthetics): Global leader in HA-based dermal fillers (Juvéderm) and aesthetics — competes with YooYoung's DivaViva series in international aesthetics markets and sets the bar for clinical and regulatory depth.
• Hanmi Pharmaceutical: Larger Korean pharma with global licensing-out expertise and a broad OSD/injectable pipeline — comparable GTM model (in/out-licensing, global partnerships) but operating at significantly greater scale.
• Galderma: Global dermatology and aesthetics company with leading HA filler franchises (Restylane, Emervel) — directly competes with YooYoung's HA fillers in regulated export markets and represents the global benchmark.

Direct peers

• Medytox: Korean aesthetics biotech specializing in botulinum toxin and HA-based injectable products — a direct competitor in the same HA filler and injectable aesthetics category as YooYoung's DivaViva.
• Ildong Pharmaceutical: Korean pharma of similar vintage producing finished drug products across OSD, injectables, and OTC segments with comparable manufacturing scale and export presence.
• Corestem: Korean biotech that co-developed and supplies NeuroNata-R (ALS stem cell therapy) with YooYoung. A closely linked therapeutic-area peer in stem cell therapy for degenerative disease.
• JW Pharmaceutical: Korean mid-sized pharma with OSD, injectable, and specialty drug manufacturing — similar product mix, GMP-certified facilities, and export orientation.
• Hugel: Korean specialty pharma with overlapping HA filler (TheChae/Wellage) and botulinum toxin aesthetics portfolios, plus injectable therapeutics — a closely comparable Korean peer in both aesthetics and injectable pharma.
• Daewoong Pharmaceutical: Mid-to-large Korean pharma with a diversified OSD, injectable, and aesthetics portfolio including Nabota (botulinum toxin) — directly comparable in business model, manufacturing footprint, and export-driven GTM.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/yypharm

Compliance10 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about YooYoung Pharmaceutical